BRKR: SEC Form 10-Q filed by Bruker Corporation
Bruker files Q3 2026 10-Q with 152.7M common shares outstanding; text excerpt shows no revenue, EPS or guidance figures.
What this filing says
Bruker Corporation filed its quarterly report for the period ended September 30, 2026. The excerpt provided is mostly the cover page, showing 152,722,385 common shares outstanding as of November 2, 2026, and the listing of its common stock and 6.375% mandatory convertible preferred stock on Nasdaq. The financial statement lines included are only labels without figures, so the filing does not give enough detail here to judge results.
Key figures
- Common shares outstanding
- 152,722,385 shares
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Mandatory convertible preferred stock:
- A preferred share that must convert into common stock on a set date, so holders end up owning common shares later.
FAQ
How many Bruker common shares were outstanding when the filing was made?
The filing reports 152,722,385 shares of common stock outstanding at November 2, 2026.
What is the reporting period covered by Bruker's 10-Q?
The quarterly report covers the period ended September 30, 2026.
Historical context for BRKR
Across the 27 sessions after earlier BRKR headlines, the stock closed higher 13 times and lower 14 times, with a median move of 1.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BRKR | SPY |
|---|---|---|---|
| Nov 4, 2026 | Bruker Reports Third Quarter 2026 Financial Results | +12.9% | +1.7% |
| Oct 21, 2026 | Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast | +5.7% | +0.5% |
| Oct 14, 2026 | Bruker downgraded by Analyst with a new price target | -1.1% | -1.1% |
| Oct 6, 2026 | Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution | -5.3% | +0.5% |
| Sep 28, 2026 | Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research | -1.4% | -0.7% |
| Sep 21, 2026 | Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley | +0.3% | +1.6% |
Keep researching BRKR
- BRKR financial statementsRevenue, profit, cash flow and balance sheet from Bruker Corporation's SEC filings.
- What is Form 10-Q?The quarterly report US public companies file with the SEC for each of the first three fiscal quarters, with unaudited financial statements and MD&A.
- Form 10-K vs 10-QThe difference between a 10-K and a 10-Q: what each report contains, filing deadlines by company size, audited vs reviewed financials, and which sections to read first.
- BRKR insider tradesEvery buy and sale reported by Bruker Corporation officers, directors and large holders.
- BRKR earnings historyPast Bruker Corporation earnings releases, newest first.
- Market cap
- 30-day
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
Follow BRKR and get a push notification the moment its next story breaks.